Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Dec 2020
Randomized Controlled TrialUstekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
The ongoing UNIFI long-term extension evaluates subcutaneous ustekinumab for moderate-to-severe ulcerative colitis (UC) from weeks 44 through 220. ⋯ The efficacy of ustekinumab in patients with UC was sustained through 92 weeks. No new safety signals were observed (ClinicalTrials.gov number, NCT02407236).